Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.

Christophe HézodePiero L AlmasioStefan BourgeoisPeter BuggischAshley BrownMoises DiagoYves HorsmansLawrence SerfatyFerenc SzalayGiovanni B GaetaRamon PlanasMichael SchlagIsabelle Lonjon-DomanecEdmund OmoruyiRalph DeMasiStefan Zeuzem

Published in: Liver international : official journal of the International Association for the Study of the Liver (2017)

Simeprevir+daclatasvir demonstrated strong antiviral activity and was well-tolerated in patients with hepatitis C virus genotype 1b infection, advanced liver disease and a high prevalence of comorbidities. However, viral breakthrough occurred in seven patients, making this regimen unsatisfactory.

Keyphrases

hepatitis c virus
human immunodeficiency virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
sars cov
peritoneal dialysis
replacement therapy
antiretroviral therapy
hiv infected
preterm birth